A Phase I/II, Open-label, Uncontrolled, Single-dose, Dose-ascending, Multi-centre Trial Investigating an Adeno-associated Viral Vector Containing a Codon-optimized Human Factor IX Gene (AAV5-hFIX) Administered to Adult Patients With Severe or Moderately Severe Hemophilia B

Study Summary

This study evaluates how safe gene therapy treatment with AAV5-hFIX is in adult patients with severe or moderately severe hemophilia B and severe bleeding type.

Interventions

Study Locations

Facility	City	State	Country
uniQure Investigative Site	Copenhagen		Denmark
uniQure Investigative Site	Berlin		Germany
uniQure Investigative Site	Frankfurt		Germany
uniQure Investigative Site	Amsterdam		Netherlands
uniQure Investigative Site	Groningen		Netherlands
uniQure Investigative Site	Rotterdam		Netherlands
uniQure Investigative Site	Utrecht		Netherlands

Official Trial Information

View on ClinicalTrials.gov